Intelligence / Healthtech / New Clinical Trials / Chengdu Suncadia Medicine Co., Ltd.
Chengdu Suncadia Medicine Co., Ltd.
16 Nov 2026: Trial registered · A Clinical Trial on the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-9308 Tablet as Monotherapy or Combination Therapy in Participants With Advanced Solid Tumors. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 16 Nov 2026
- Title
- A Clinical Trial on the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-9308 Tablet as Monotherapy or Combination Therapy in Participants With Advanced Solid Tumors
- Conditions
- Solid Tumor
- Phase
- Phase 1, Phase 2
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Countries
- China
- Country
- China
- Reference
- NCT07940439
- Location
- China
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Find the decision makers at Chengdu Suncadia Medicine Co., Ltd.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Across AOS Research
Other records for Chengdu Suncadia Medicine Co., Ltd. in our registers.
More from China
New Clinical Trials
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.